Compare GNS & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNS | CALC |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.8M | 91.5M |
| IPO Year | 2022 | N/A |
| Metric | GNS | CALC |
|---|---|---|
| Price | $0.67 | $6.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | ★ 1.7M | 144.6K |
| Earning Date | 09-23-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,749,894.00 | N/A |
| Revenue This Year | $82.78 | N/A |
| Revenue Next Year | $85.90 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.21 | $1.42 |
| 52 Week High | $1.92 | $6.40 |
| Indicator | GNS | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 49.42 | 76.69 |
| Support Level | $0.62 | $4.64 |
| Resistance Level | $0.76 | $5.34 |
| Average True Range (ATR) | 0.06 | 0.51 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 52.91 | 90.04 |
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company's business consists of two reportable business segments: Education, which involves entrepreneur education, management consultancy, and business development tools; and Campus, consisting of resorts, retreats, and co-working cafes for entrepreneurs. It derives the majority of its revenue from the Education segment. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America. The company derives maximum revenue from Europe/Middle East/Africa.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.